Natera is projected to report Q3 2026 revenue of $702.9 million and a narrowed loss per share of $0.28, as the stock trades around $388.78 against a consensus price target of $416.39.
Investors are laser-focused on Signatera oncology test volumes, which analysts expect to reach approximately 318,000 units for the quarter.
This robust growth, estimated at 57% year-over-year, remains the primary engine for Natera's transition toward cash flow break-even. Wall Street is also closely monitoring gross margin sustainability and potential updates to the company's fiscal 2026 revenue guidance following significant market share gains in minimal residual disease testing.